TerSera® Announces Addition of Cetirizine as an Adjunctive Treatment to Interim CDC Guidelines for Managing Adverse Reactions After COVID-19 Vaccination

Press Release
February 23, 2021

Download PDF

View previous article
View next article

Unless otherwise specified, all company and product names appearing in this Website are trademarks owned by or licensed to TerSera Therapeutics LLC, its subsidiaries or affiliates. No use of any TerSera trademark, trade name, or trade dress in this Website may be made without the prior written authorization of TerSera, except to identify the product or services of the company.